| Subject |
The board of directors of the Company approved removal of the noncompete clause for managers. |
- Date of the board of directors resolution:2023/04/12
- Name and title of the managerial officer with permission to engage in competitive conduct:The general president, Chih-Hui Cheng.
- Items of competitive conduct in which the officer is permitted to engage:
(1)Director of the Microbio (Shanghai) Co., Ltd.(Representative Director of the Oneness Biotech Co., Ltd.)
(2)Director of the Microbio Singapore Pet. Ltd.(Representative Director of the Oneness Biotech Co., Ltd.)
- Period of permission to engage in the competitive conduct:For the duration of employment as a manager of the Company.
- Circumstances of the resolution (please describe the results of voting in accordance with Article 32 of the Company Act):The board of directors approved the proposal unanimously with no changes.
- If the permitted competitive conduct belongs to the operator of a mainland China enterprise, the name and title of the managerial officer (if it is not the operator of a mainland China enterprise, please enter “N/A” below):The general president, Chih-Hui Cheng.
- Company name of the mainland China enterprise and the officer’s position in the enterprise:Director and Financial Officer of the Microbio(Shanghai) Co., Ltd.
- Address of the mainland China enterprise:1188 Guangxing Road,Songjiang District, Shanghai China.
- Operations of the mainland China enterprise:Production and sales of health care capsules and lozenges, Chinese herbal medicines, Chinese herbal extracts, Chinese patent medicine processing and production, new drug research and development, etc.
- Impact on the company’s finance and business:
Microbio (Shanghai) is invested by the Company by adopting the equity method through which the profits or losses is recognized.
- If the managerial officer or director has invested in the mainland China enterprise, the monetary amount of the investment and the officer or director’s shareholding ratio:
(1) The monetary amount of the investment: USD 372,000.
(2) The shareholding ratio: 0.7094%.
- Any other matters that need to be specified:None.
|
